Vedana Therapeutics
Summary active Updated Jun 3, 2026This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.
Founders
About
Vedana Therapeutics is a Seattle-based biotech company developing next-generation antibody therapies for migraine prevention 12. The company emerged from stealth on June 17, 2026 with $46 million in Series A financing 1. Vedana’s lead program is a subcutaneously delivered next-generation anti-PACAP antibody for migraine prevention, and its second program targets both PACAP and CGRP pathways 23. The company is led by co-founder and CEO Anurag Agrawal, Ph.D., and co-founder and Chief Scientific Officer Leon Garcia, Ph.D., with executive chair Rob Lenz, M.D., Ph.D., and Marcelo Bigal, M.D., Ph.D. on the board 1.
Funding History
| Date | Round | Amount | Lead | Co-investors |
|---|---|---|---|---|
| 2026-06-17 | Series A | $46M | Westlake BioPartners, Canaan Partners | Dawn Biopharma, Alexandria Venture Investments 123 |
What Investors Say
No independently sourced investor quotes available at this time.
What Founders Say
No independently sourced founder quotes available at this time.
Sources
-
BusinessWire (via FinancialContent), “Vedana Therapeutics Launches With $46 Million Series A Financing to Advance Next-Generation Migraine Therapies,” June 17, 2026, accessed June 2026. https://www.financialcontent.com/article/bizwire-2026-6-17-vedana-therapeutics-launches-with-46-million-series-a-financing-to-advance-next-generation-migraine-therapies↩↩↩↩
-
Fierce Biotech, “Vedana Therapeutics surfaces with $46M to develop next generation of migraine prevention therapies,” June 17, 2026, accessed June 2026. https://www.fiercebiotech.com/biotech/vedana-therapeutics-surfaces-46m-develop-next-gen-migraine-therapy↩↩↩
-
Endpoints News, “Migraine biotech Vedana Therapeutics makes its debut with $46M Series A,” June 17, 2026, accessed June 2026. https://endpoints.news/migraine-biotech-vedana-therapeutics-makes-its-debut-with-46m-series-a/↩↩